Apollo Hospitals Enterprise Ltd: Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Reflect Improved Price Attractiveness

As of 12 Aug 2026, Apollo Hospitals trades at ₹8,751, down 1.91% from the previous close of ₹8,921. Despite the recent dip, the stock remains near its 52-week high of ₹9,326.80, well above its 52-week low of ₹6,680.00. The company’s price-to-earnings (P/E) ratio currently stands at 64.32, a figure that, while elevated, has been reassessed from a fair to an attractive valuation grade by MarketsMOJO analysts. This reclassification signals a more compelling entry point for investors given the company’s growth prospects and earnings quality.

Complementing the P/E ratio, the price-to-book value (P/BV) is at 13.27, reflecting the premium investors place on Apollo’s brand, operational scale, and asset quality. The enterprise value to EBITDA (EV/EBITDA) multiple is 35.07, slightly lower than some sector peers, indicating relatively better earnings efficiency on an enterprise value basis.

Comparison with Industry Peers Highlights Relative Value

When compared to Manipal Health, a key competitor in the hospital industry, Apollo’s valuation appears more attractive. Manipal Health’s P/E ratio is significantly higher at 100.81, and its EV/EBITDA multiple stands at 38.39, categorising it as very expensive in contrast. This disparity underscores Apollo’s improved relative valuation, especially considering its strong operational metrics and market position.

Moreover, Apollo’s PEG ratio of 1.82 suggests that the stock’s price growth is reasonably aligned with its earnings growth, a positive sign for investors seeking sustainable returns. The dividend yield remains modest at 0.23%, consistent with the company’s focus on reinvestment and expansion rather than high dividend payouts.

Robust Financial Performance Supports Valuation Upgrade

Apollo Hospitals’ return on capital employed (ROCE) is 18.27%, while return on equity (ROE) stands at 20.63%, both indicative of efficient capital utilisation and strong profitability. These figures reinforce the company’s ability to generate shareholder value and justify its premium valuation multiples.

Stock returns further validate the company’s performance. Year-to-date (YTD), Apollo has delivered a 24.26% return, significantly outperforming the Sensex’s negative 8.29% over the same period. Over one year, the stock has appreciated by 20.63%, while the Sensex declined by 3.04%. Longer-term returns are even more impressive, with a three-year gain of 78.54% and a five-year return of 117.43%, dwarfing the Sensex’s respective 19.64% and 43.33% gains. Over a decade, Apollo’s stock has surged 531.18%, compared to the Sensex’s 180.53%, highlighting its sustained growth trajectory.

Market Capitalisation and Mojo Score Indicate Strong Buy Sentiment

Apollo Hospitals is classified as a large-cap stock, reflecting its substantial market capitalisation and leadership in the hospital sector. The company’s Mojo Score, a comprehensive rating metric by MarketsMOJO, has improved to 78.0, accompanied by an upgrade in Mojo Grade from Hold to Buy as of 11 May 2026. This upgrade reflects enhanced confidence in Apollo’s earnings growth, valuation, and overall market positioning.

The recent downgrade in the stock price by 1.91% on the day of reporting should be viewed in the context of broader market fluctuations rather than a fundamental shift. The stock’s resilience and strong fundamentals continue to make it an attractive proposition for long-term investors.

Valuation Multiples in Historical Context

Historically, Apollo Hospitals has traded at elevated multiples due to its dominant market share and consistent earnings growth. The current P/E of 64.32, while high compared to the broader market, is justified by the company’s superior return ratios and growth outlook. The shift from a fair to an attractive valuation grade suggests that the stock is now priced more favourably relative to its historical averages and sector peers.

Similarly, the EV to capital employed ratio of 8.35 and EV to sales multiple of 5.24 indicate efficient utilisation of capital and revenue generation capabilities. These metrics, combined with a PEG ratio below 2, signal that Apollo’s valuation is balanced against its growth prospects, making it a compelling choice for investors seeking exposure to the healthcare sector.

Investor Takeaway: Balancing Growth and Valuation

Investors analysing Apollo Hospitals Enterprise Ltd. should consider the company’s strong fundamentals, consistent return ratios, and superior long-term stock performance relative to the Sensex. The recent upgrade in valuation grade to attractive, supported by a favourable P/E and PEG ratio, suggests that the stock is reasonably priced for its growth potential.

While the stock trades at premium multiples, these are justified by Apollo’s leadership in the hospital sector, robust operational metrics, and sustained earnings growth. The modest dividend yield indicates a focus on reinvestment, which could fuel further expansion and profitability.

Given the company’s large-cap status and improved Mojo Grade of Buy, Apollo Hospitals remains a compelling option for investors seeking exposure to the healthcare sector with a blend of growth and relative valuation comfort. However, investors should remain mindful of market volatility and sector-specific risks when considering entry points.

Conclusion

Apollo Hospitals Enterprise Ltd. has demonstrated a meaningful shift in valuation attractiveness, supported by strong financial performance and market leadership. Its improved valuation grade, combined with a solid Mojo Score and Buy rating, positions the stock favourably for investors aiming to capitalise on India’s growing healthcare demand. The stock’s historical outperformance versus the Sensex further reinforces its appeal as a long-term investment.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today